

## **Lapse and Forfeit of Unlisted Conditional Performance Rights**

Melbourne, Australia, August 23, 2016

Clinuvel Pharmaceuticals Ltd (**ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY**) wishes to advise in accordance with the terms and conditions of issue that the following unquoted conditional performance rights have lapsed and forfeited:

<b>Class</b>	<b>Number</b>	<b>Exercise price</b>
CUVAK Conditional Performance Rights subject to various performance milestones, issued various dates under the 2009 and 2014 Plans	4,000	\$Nil

Consequently, there are now 1,907,660 unlisted conditional performance rights on issue.

- End -

**For more information contact:**

Darren Keamy  
Company Secretary  
Clinuvel Pharmaceuticals Limited  
T: +61 3 9660 4900  
E: [investorrelations@clinuvel.com](mailto:investorrelations@clinuvel.com)

This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause Clinuvel's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE® (afamelanotide 16mg); that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that Clinuvel may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US.

Level 5, 160 Queen Street      T +61 3 9660 4900    [www.clinuvel.com](http://www.clinuvel.com)  
Melbourne, Victoria 3000      F +61 3 9660 4999  
Australia